Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elite Pharmaceuticals Inc. (ELTP : OTC)

• Company Description    Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $0.25 Daily Weekly Monthly 20 Day Moving Average: 790,630 shares Shares Outstanding: 1,077.14 (millions) Market Capitalization: $269.07 (millions) Beta: 0.34 52 Week High: $0.69 52 Week Low: $0.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.22% 2.28% 12 Week -32.98% -34.61% Year To Date -49.05% -54.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 165 LUDLOW AVENUE - NORTHVALE,NJ 07647 USA ph: 201-750-2646 fax: 201-750-2755 dianne@elitepharma.com http://www.elitepharma.com

• General Corporate Information    Officers Nasrat Hakim - Chief Executive Officer; President and Chairman of Carter Ward - Chief Financial Officer Barry Dash - Director Jeffrey Whitnell - Director Davis Caskey - Director Peer Information Elite Pharmaceuticals Inc. (GSAC) Elite Pharmaceuticals Inc. (CASIF) Elite Pharmaceuticals Inc. (ALCD.) Elite Pharmaceuticals Inc. (OMNN) Elite Pharmaceuticals Inc. (CGPI.) Elite Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 28659T200 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 1,077.14 Most Recent Split Date: (:1) Beta: 0.34 Market Capitalization: $269.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 12.49 PEG Ratio: - Price Ratios Price/Book: 2.57 Price/Cash Flow: 9.36 Price / Sales: 1.91 EPS Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -19.54% vs. Previous Quarter: -20.60% ROE 09/30/26 - - 06/30/26 - 44.58 03/31/26 - 37.06 ROA 09/30/26 - - 06/30/26 - 29.54 03/31/26 - 21.67 Current Ratio 09/30/26 - - 06/30/26 - 3.76 03/31/26 - 6.45 Quick Ratio 09/30/26 - - 06/30/26 - 2.97 03/31/26 - 5.22 Operating Margin 09/30/26 - - 06/30/26 - 27.32 03/31/26 - 17.95 Net Margin 09/30/26 - - 06/30/26 - 40.19 03/31/26 - 30.14 Pre-Tax Margin 09/30/26 - - 06/30/26 - 46.16 03/31/26 - 38.16 Book Value 09/30/26 - - 06/30/26 - 0.10 03/31/26 - 0.09 Inventory Turnover 09/30/26 - - 06/30/26 - 3.59 03/31/26 - 3.52 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.03 03/31/26 - 0.04 Debt-to-Capital 09/30/26 - - 06/30/26 - 3.26 03/31/26 - 3.57

Powered by Zacks Investment Research ©